CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 31 enrolled
Drug / intervention
Elbasvirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01797536
NCT01797536Phase 1Completed
CompareCT.gov

A Three-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-8742

Merck Sharp & Dohme LLC·interventional·Posted Feb 22, 2013·Updated Oct 25, 2018

In Brief

A Phase 1 clinical trial evaluating Elbasvir for Hepatic Insufficiency. Completed, enrolled 31 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) profile of elbasvir (MK-8742) after a single dose to participants with mild, moderate, or severe hepatic insufficiency compared with healthy controls.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Insufficiency
CountriesUnited States
CollaboratorsCelerion

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 22, 2013
Enrollment StartMar 6, 2013
Primary CompletionAug 20, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.4 years ago

Interventions

Elbasvirdrug